Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Current Liabilities (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Total Current Liabilities for 6 consecutive years, with $12.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 65.98% to $12.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.1 million through Dec 2025, up 65.98% year-over-year, with the annual reading at $12.1 million for FY2025, 65.98% up from the prior year.
  • Total Current Liabilities hit $12.1 million in Q4 2025 for Insight Molecular Diagnostics, up from $7.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $19.8 million in Q2 2021 to a low of $6.7 million in Q2 2025.
  • Historically, Total Current Liabilities has averaged $10.5 million across 5 years, with a median of $9.6 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: surged 189.02% in 2021 and later crashed 45.83% in 2023.
  • Year by year, Total Current Liabilities stood at $14.1 million in 2021, then fell by 14.26% to $12.1 million in 2022, then tumbled by 40.57% to $7.2 million in 2023, then grew by 1.13% to $7.3 million in 2024, then soared by 65.98% to $12.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for IMDX at $12.1 million in Q4 2025, $7.7 million in Q3 2025, and $6.7 million in Q2 2025.